|
1
|
Yen JC, Lin HL, Hsu CA, Li YC and Hsu MH:
Atrial fibrillation and coronary artery disease as risk factors of
retinal artery occlusion: a nationwide population-based study.
BioMed Res Int. 2015:3746162015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Antoun JS, Slim EA, Hemade AI, Awada S,
Fakhoury HW and Cherfan CG: Idiopathic central retinal artery
occlusion in an eight-year-old girl. J Fr Ophtalmol. 39:e1–e3.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Naff NJ, Carhuapoma JR, Williams MA,
Bhardwaj A, Ulatowski JA, Bederson J, Bullock R, Schmutzhard E,
Pfausler B, Keyl PM, Tuhrim S and Hanley DF: Treatment of
intraventricular hemorrhage with urokinase : Effects on 30-Day
survival. Stroke. 31:841–847. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wardlaw JM, Murray V, Berge E, Del ZG,
Sandercock P, Lindley RL and Cohen G: Recombinant tissue
plasminogen activator for acute ischaemic stroke: An updated
systematic review and meta-analysis. Lancet. 379:2364–2372. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schmidt DP, Schulte-Mönting J and
Schumacher M: Prognosis of central retinal artery occlusion: local
intraarterial fibrinolysis versus conservative treatment. AJNR Am J
Neuroradiol. 23:1301–1307. 2002.PubMed/NCBI
|
|
6
|
Hayreh SS and Zimmerman MB: Central
retinal artery occlusion: visual outcome. Am J Ophthalmol.
140:376–391. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wardlaw JM, Murray V, Berge E and Del
Zoppo GJ: Thrombolysis for acute ischaemic stroke. Cochrane
Database Syst Rev. 7:CD0002132009.
|
|
8
|
Yokoyama S, Manabe Y, Fujii D, Ikeda-Sakai
Y, Narai H, Omori N and Abe K: Intravenous tissue plasminogen
activator therapy for an acute ischemic stroke patient with later
diagnosed unilateral moyamoya syndrome. J Stroke Cerebrovasc Dis.
22:1190–1192. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou ZG, Wang RL and Yu KL: Myocardial
infarction following recombinant tissue plasminogen activator
treatment for acute ischemic stroke: a dangerous complication. Chin
Med J (Engl). 125:2775–2776. 2012.PubMed/NCBI
|
|
10
|
Hattenbach LO, Kuhli-Hattenbach C,
Scharrer I and Baatz H: Intravenous thrombolysis with low-dose
recombinant tissue plasminogen activator in central retinal artery
occlusion. Am J Ophthalmol. 146:700–706. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen CS, Lee AW, Campbell B, Lee T, Paine
M, Fraser C, Grigg J and Markus R: Efficacy of intravenous
tissue-type plasminogen activator in central retinal artery
occlusion: report from a randomized, controlled trial. Stroke.
42:2229–2234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kattah JC, Wang DZ and Reddy C:
Intravenous recombinant tissue-type plasminogen activator
thrombolysis in treatment of central retinal artery occlusion. Arch
Ophthalmol. 120:1234–1236. 2002.PubMed/NCBI
|
|
13
|
Nowak RJ, Amin H, Robeson K and Schindler
JL: Acute central retinal artery occlusion treated with intravenous
recombinant tissue plasminogen activator. J Stroke Cerebrovasc Dis.
21:913.e5–913.e8. 2012. View Article : Google Scholar
|
|
14
|
Hazin R, Dixon JA and Bhatti MT:
Thrombolytic therapy in central retinal artery occlusion: cutting
edge therapy, standard of care therapy, or impractical therapy?
Curr Opin Ophthalmol. 20:210–218. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mach R and Procházka J: Thrombolysis in
central retinal artery occlusion using alteplase. Cesk Slov
Oftalmol. 64:245–248. 2008.(In Czech). PubMed/NCBI
|
|
16
|
Ma J, Yang X and Li Z: Research progess on
introducing thrombolytic therapy into treating retinal central
artery occlusion. Int Rev Opthalmology. 25:1–4. 2001.
|
|
17
|
Sugiura S, Iwaisako K, Toyota S and
Takimoto H: Simultaneous treatment with intravenous recombinant
tissue plasminogen activator and endovascular therapy for acute
ischemic stroke within 3 hours of onset. AJNR Am J Neuroradiol.
29:1061–1066. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wi JM and Chi M: Rhabdomyolysis presenting
as orbital apex syndrome. J Craniofac Surg. 27:e48–e50. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rodríguez Villa S, Méndez R Salazar,
Martín M Cubillas and Cuesta García M: Central retinal artery
occlusion after phacoemulsification under peribulbar anaesthesia:
pathogenic hypothesis. Arch Soc Esp Oftalmol. 91:40–43. 2016.(In
Spanish). PubMed/NCBI
|
|
20
|
Chavala SH, Williamson JF and Postel EA:
Embolic central retinal artery occlusion after subcutaneous
auricular steroid injection. Lancet. Nov 26–2015.(Epub ahead of
print).
|
|
21
|
Ahn SJ, Park KH, Ryoo NK, Hong JH, Jung C,
Yoon CH, Han MK and Woo SJ: No-reflow phenomenon in central retinal
artery occlusion: incidence, risk factors, and clinical
implications. PLoS One. 10:e01428522015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rajabi MT, Naderan M, Mohammadi SZ and
Rajabi MB: Central retinal artery occlusion following orbital tumor
resection: is rapid intervention effective? Indian J Ophthalmol.
63:678–680. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu CW, Wang J, Zhou DD, Hao JL, Liang LL,
Li XH and Hui P: Central retinal artery occlusion associated with
persistent truncus arteriosus and single atrium: a case report. BMC
Ophthalmol. 15:1372015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miller NR: Should patients with acute
central retinal artery occlusion be treated with intra-arterial
t-PA?: Comment. J Neuroophthalmol. 35:4442015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Beck KD and Hernandez L: Central retinal
artery occlusion in a 21-year-old boxer. Ophthalmology.
122:15682015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
de Castro-Abeger AH, de Carlo TE, Duker JS
and Baumal CR: Optical coherence tomography angiography compared to
fluorescein angiography in branch retinal artery occlusion.
Ophthalmic Surg Lasers Imaging Retina. 46:1052–1054. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sharma M, Prashar A, Tuli R, Sharma RK and
Mahajan VK: Atypical central retinal artery occlusion: an uncommon
cause of retinopathy and visual loss in dermatomyositis. Int J
Rheum Dis. Sep 25–2015.(Epub ahead of print). View Article : Google Scholar
|
|
28
|
Liu WD, Chen LL, Shen CY and Jiang LB:
Neuroprotective effect of compound anisodine in a mouse model with
chronic ocular hypertension. Chin Med J (Engl). 128:2652–2657.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu Y, Song C and Wang S: [The changes of
hemodynamics in ocular trauma and treatment with compound
anisodine]. Zhonghua Yan Ke Za Zhi. 32:110–113. 1996.PubMed/NCBI
|
